FDA announces proposals to prevent failures in surgical and implantable staplesApril 29, 2019The U.S. Food & Drug Administration (FDA) says it is proposing ways to better protect patients from the malfunctions, injuries, and deaths associated with surgical and implantable staples. The review comes after the FDA alerted public and health-care professionals to concerns over surgical staplers for internal use and implantable surgical staples. The alert was prompted as the result of the agency's analysis showing that from Jan. 1, 2011 to Mar. 31, 2018, it received more than 41,000 medical device reports pertaining to over 32,000 malfunctions, approximately 9,000 serious injuries, and 366 patient deaths. The most reported problems referred to staple lines opening, malformation of staples, misfiring and difficulty in firing of staples, stapler failure, and misapplied staples. These devices are commonly used in veterinary settings. The FDA's new proposals include: 1) Reclassifying surgical staplers for internal use to a higher-risk category, requiring the review and clearance of a premarket notification submission prior to marketing. The staples would be reclassified from Class I (low risk) to Class II (moderate risk) medical devices with special controls. This would require mandatory performance testing of various mechanical features, demonstration of usability and labeling comprehension such as assessing health-care professionals' ability to properly select …
SPONSORED CONTENTProtect your patients from the start.Simparica Trio (sarolaner, moxidectin, and pyrantel chewable tablets) is the first monthly preventative of its kind. Combining three ingredients for month-long protection. + Learn more
